scholarly article | Q13442814 |
review article | Q7318358 |
P356 | DOI | 10.1023/A:1021425004264 |
P698 | PubMed publication ID | 12523654 |
P2093 | author name string | A N Tony Kong | |
Khew-Voon Chin | |||
P2860 | cites work | Initial sequencing and analysis of the human genome | Q21045365 |
The Sequence of the Human Genome | Q22065842 | ||
Cloning of Nrf1, an NF-E2-related transcription factor, by genetic selection in yeast | Q24321410 | ||
Isolation of cDNA encoding the human NF-E2 protein | Q24563782 | ||
Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain | Q24609907 | ||
Cluster analysis and display of genome-wide expression patterns | Q24644463 | ||
Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H:quinone oxidoreductase1 gene | Q24649776 | ||
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma | Q27824784 | ||
Gene expression profiling predicts clinical outcome of breast cancer | Q27860732 | ||
Quantitative monitoring of gene expression patterns with a complementary DNA microarray | Q27861102 | ||
hMAF, a small human transcription factor that heterodimerizes specifically with Nrf1 and Nrf2 | Q28241711 | ||
Gene-expression profiles predict survival of patients with lung adenocarcinoma | Q29614443 | ||
High density synthetic oligonucleotide arrays | Q29616560 | ||
Application of complementary DNA microarray technology to carcinogen identification, toxicology, and drug safety evaluation. | Q30790297 | ||
Mutational analysis using oligonucleotide microarrays | Q33755554 | ||
Signal transduction events elicited by cancer prevention compounds | Q34338131 | ||
Gene expression of TPA induced differentiation in HL-60 cells by DNA microarray analysis | Q34368407 | ||
Induction of xenobiotic enzymes by the MAP kinase pathway and the antioxidant or electrophile response element (ARE/EpRE). | Q34478999 | ||
Pharmacogenomics, regulation and signaling pathways of phase I and II drug metabolizing enzymes | Q34946568 | ||
Gene microarray identification of redox and mitochondrial elements that control resistance or sensitivity to apoptosis | Q35079106 | ||
Regulation of the antioxidant response element by protein kinase C-mediated phosphorylation of NF-E2-related factor 2 | Q35814343 | ||
Number of CpG islands and genes in human and mouse | Q36738077 | ||
Activation of mitogen-activated protein kinase pathways induces antioxidant response element-mediated gene expression via a Nrf2-dependent mechanism | Q38308355 | ||
Assembly, annotation, and integration of UNIGENE clusters into the human genome draft | Q40414920 | ||
Phosphatidylinositol 3-kinase, not extracellular signal-regulated kinase, regulates activation of the antioxidant-responsive element in IMR-32 human neuroblastoma cells | Q43556602 | ||
26 S proteasome-mediated degradation of topoisomerase II cleavable complexes. | Q43730370 | ||
Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray. | Q54040435 | ||
The toxicity of menadione and mitozantrone in human liver-derived Hep G2 hepatoma cells | Q60517658 | ||
Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling | Q61910882 | ||
P433 | issue | 12 | |
P921 | main subject | pharmacogenomics | Q1152227 |
P304 | page(s) | 1773-1778 | |
P577 | publication date | 2002-12-01 | |
P1433 | published in | Pharmaceutical Research | Q7180737 |
P1476 | title | Application of DNA microarrays in pharmacogenomics and toxicogenomics | |
P478 | volume | 19 |
Q38107202 | A glance at DNA microarray technology and applications |
Q35605265 | Advances in pharmacogenomic research and development |
Q24805862 | Analysis of host response to bacterial infection using error model based gene expression microarray experiments. |
Q94101549 | Current Awareness on Comparative and Functional Genomics |
Q28390730 | Designing toxicogenomics studies that use DNA array technology |
Q40665215 | Differential responses from seven mammalian cell lines to the treatments of detoxifying enzyme inducers. |
Q36808197 | Effects of cardiotonic steroids on dermal collagen synthesis and wound healing |
Q38163465 | Emerging technologies and challenges for better and safer drugs |
Q23914178 | Environmental health research in the post-genome era: new fields, new challenges, and new opportunities |
Q51570050 | Gene expression signature for recurrence in stage III colorectal cancers. |
Q33708586 | Magnetic scanometric DNA microarray detection of methyl tertiary butyl ether degrading bacteria for environmental monitoring |
Q35207557 | Microarray technology--an intellectual property retrospective |
Q36467321 | New strategies in drug discovery |
Q34981527 | Novel multistranded, alternative, plasmid and helical transitional DNA and RNA microarrays: implications for therapeutics |
Q85241229 | RNA and DNA Microarrays |
Q37121662 | Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. |
Q30986903 | The use of toxicogenomic data in risk assessment: a regulatory perspective |
Q37380576 | Variability of DNA microarray gene expression profiles in cultured rat primary hepatocytes. |
Search more.